With a new, experienced management team and a $47-million series A financing in place, closely-held LENZ Therapeutics is gearing up for a pivotal trial of its aceclidine once-daily eye drop to treat presbyopia, the...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Cantor halves Ardelyx PT to $7 from $14; maintains OW rating
Cantor Fitzgerald slashed its price target for Ardelyx (NASDAQ:ARDX) to $7 from $14 after the company received a complete response letter from the FDA for its NDA for tenapanor to control serum phosphorus in adult...
EyeGate Pharma names Brian Strem as president and CEO
EyeGate Pharmaceuticals (NASDAQ:EYEG) appointed Brian Strem, Ph.D., as president, CEO and a director, effective immediately. He replaces acting CEO, Franz Obermayr, Ph.D., who reassumes his position as EVP clinical...
Deep Genomics raises $180-million (U.S.) to develop drugs discovered by AI
University of Toronto spinout, Deep Genomics, raised $180-million (U.S.) led by Softbank’s Vision Fund 2 to bankroll its efforts to discover and develop drugs using artificial intelligence. The funding group included...
Talkiatry completes $20-million Series A funding
Closely-held Talkiatry, a provider of accessible in-network psychiatric care, completed its $20-million a Series A funding, of which $15-million was led by Left Lane Capital, with participation from Dr. Richard Park...
FDA clears Asensus Surgical 510(k) for articulating instruments
Asensus Surgical (NYSE American:ASXC) received FDA 510(k) clearance for 5 mm diameter articulating instruments, adding to the Senhance Surgical System robotic technology platform. Articulating instruments offer better...
Cantor starts Nyxoah at OW; PT $43
Cantor Fitzgerald initiated coverage of Nyxoah SA (NASDAQ:NYXH) with an “overweight” rating and 12-month price target of $43, citing the company’s “pipeline and uniquely differentiated product”. The stock closed at $32...
Canaccord starts CVRx at buy; PT $30
Canaccord Genuity initiated coverage of CVRx (NASDAQ:CVRX) with a “buy” rating and price target of $30. The stock closed at $20.22 on July 23. “We believe that CVRx is uniquely positioned in addressing significant unmet...
Stifel starts Acumen Pharma at buy; PT $27
Stifel launched coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $27 price target. The stock closed at $17.08 on July 23. Acumen is a biotechnology company focused on the development of a next...
Cybin receives conditional listing approval from NYSE American
Cybin (NEO:CYBN; OTCQB:CLXPF) has received conditional listing approval from the NYSE American stock exchange, under the ticker symbol, CYBN. In a statement, Doug Drysdale, CEO of Cybin, said conditional listing...
Cantor starts SELLAS Life Sciences at OW; PT $18
Cantor Fitzgerald launched coverage of SELLAS Life Sciences (NASDAQ:SLS) with an “outperform” rating and $18 price target. The stock closed at $8.60 on July 20. SELLAS is a late-stage immune-oncology company that is...
Stifel starts GH Research at buy; PT $26
Stifel launched coverage of GH Research PLC (NASDAQ:GHRS) with a “buy” rating and price target of $26. The stock closed at $17.25 on July 19. “We believe GH offers an attractive way to invest in the psychedelics space...
Analysts start Alpha Teknova at outperform, buy
Analysts for William Blair and BTIG initiated coverage of Alpha Teknova (NASDAQ:TKNO) with “outperform” and “buy” ratings, respectively, citing the company’s exposure to several large, rapidly growing markets. “In...
Just a few of the companies we’ve highlighted along the way
